DK0831821T3 - Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen - Google Patents

Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen

Info

Publication number
DK0831821T3
DK0831821T3 DK96915877T DK96915877T DK0831821T3 DK 0831821 T3 DK0831821 T3 DK 0831821T3 DK 96915877 T DK96915877 T DK 96915877T DK 96915877 T DK96915877 T DK 96915877T DK 0831821 T3 DK0831821 T3 DK 0831821T3
Authority
DK
Denmark
Prior art keywords
norcisapride
treatment
optically pure
digestive disorders
isomer
Prior art date
Application number
DK96915877T
Other languages
Danish (da)
English (en)
Inventor
A K Gunnar Aberg
John R Mccullough
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK0831821T3 publication Critical patent/DK0831821T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96915877T 1995-06-07 1996-05-17 Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen DK0831821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,570 US5712293A (en) 1995-06-07 1995-06-07 Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
PCT/US1996/007159 WO1996040133A1 (en) 1995-06-07 1996-05-17 Optically pure (-) norcisapride for treating digestive tract disorders

Publications (1)

Publication Number Publication Date
DK0831821T3 true DK0831821T3 (da) 2004-11-22

Family

ID=23928664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96915877T DK0831821T3 (da) 1995-06-07 1996-05-17 Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen

Country Status (11)

Country Link
US (4) US5712293A (de)
EP (2) EP1462104B1 (de)
JP (1) JPH11510477A (de)
AT (2) ATE352304T1 (de)
AU (1) AU720407B2 (de)
CA (1) CA2224005A1 (de)
DE (2) DE69633016T2 (de)
DK (1) DK0831821T3 (de)
ES (2) ES2276194T3 (de)
PT (1) PT831821E (de)
WO (1) WO1996040133A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
AU780107B2 (en) * 1996-07-19 2005-03-03 Sepracor, Inc. Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
ES2180032T3 (es) * 1996-10-15 2003-02-01 Janssen Pharmaceutica Nv Procedimiento para preparar un compuesto intermedio util en la sintesis de cisaprida.
CN1196681C (zh) * 1997-07-11 2005-04-13 詹森药业有限公司 (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途
ES2237117T3 (es) 1998-06-15 2005-07-16 Sepracor Inc. Uso de (-)norcisaprida opticamente pura en el tratamiento del sindrome del intestino irritable.
EP1464333A3 (de) * 1998-06-15 2004-12-15 Sepracor Inc. Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US7482365B2 (en) * 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
AU2003211102B2 (en) * 2002-02-13 2010-03-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
JP4588325B2 (ja) * 2002-04-15 2010-12-01 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
PL374241A1 (en) * 2002-04-15 2005-10-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
MXPA04011426A (es) 2002-05-17 2005-10-19 Univ Yale Metodo para tratar la hepatitis.
MXPA04012167A (es) * 2002-06-05 2005-09-21 Univ Yale Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis.
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
KR101351454B1 (ko) * 2005-08-31 2014-01-14 아메데온, 인코포레이티드 위장 및 중추 신경계 장애의 치료에 유용한 입체이성질체 화합물의 합성 방법 및 중간 생성물
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639002A (en) * 1970-04-06 1972-02-01 Gulf & Western Metals Forming Seat construction
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
AU720407B2 (en) 2000-06-01
DE69636877D1 (de) 2007-03-15
EP0831821B1 (de) 2004-07-28
DE69636877T2 (de) 2007-05-31
ES2276194T3 (es) 2007-06-16
US5877189A (en) 1999-03-02
EP1462104A1 (de) 2004-09-29
WO1996040133A1 (en) 1996-12-19
DE69633016T2 (de) 2004-12-23
EP1462104B1 (de) 2007-01-24
ATE271870T1 (de) 2004-08-15
US6313144B1 (en) 2001-11-06
CA2224005A1 (en) 1996-12-19
ATE352304T1 (de) 2007-02-15
PT831821E (pt) 2004-11-30
EP0831821A1 (de) 1998-04-01
JPH11510477A (ja) 1999-09-14
DE69633016D1 (de) 2004-09-02
US6156770A (en) 2000-12-05
AU5753396A (en) 1996-12-30
ES2222480T3 (es) 2005-02-01
US5712293A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
DK0831821T3 (da) Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen
DK0806948T3 (da) Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin
NO983636L (no) FremgangsmÕte for behandling av brekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid
DK0659410T3 (da) Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger
DK1020461T3 (da) Magnesiumslat af (-)enantiomeren af omeprazol og anvendelse af dette
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
ATE251139T1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
DK0434394T3 (da) Forbindelser til behandling af inflammatorisk tarmsygdom
DK0966277T3 (da) Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
DK0730865T3 (da) Anvendelse af serotonin- og dopaminreceptor-blokkere til behandling af sindslidelser, som skyldes cerebrovasculær sygdom
NO985299D0 (no) Preparat av prostaglandin I-derivat med langsom frigj°ring
NO20001343D0 (no) Fremgangsmåter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol
DK1124556T3 (da) Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme
DK0656209T3 (da) Melatoninderivater til anvendelse ved behandling af desynkroniseringsforstyrrelser
DK0814791T3 (da) Aminotetralin-derivat til behandlingen af cardiovaskulære sygdomme
ATE248168T1 (de) Racemisierung von r,s-dioxo- benzylpyrrolopiperidin
NO894384L (no) Forbindelser for behandling av urininkontinens.
NZ512684A (en) Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders
ATE236634T1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
DK0661974T3 (da) Fremgangsmåde og præparater til behandling af infektion under anvendelse af optisk ren (R)-lomefloxacin
DK0429324T3 (da) Anvendelse af N-methyl-2-(3pyridyl)-tetrahydrothiopyran-2-carbothioamid-1-oxid til fremstilling af lægemidler beregnet til behandling af coronarinsufficiens